Wulfkuhle Julia D, Liotta Lance A, Petricoin Emanuel F
NCI/FDA Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.
Nat Rev Cancer. 2003 Apr;3(4):267-75. doi: 10.1038/nrc1043.
The ability of physicians to effectively treat and cure cancer is directly dependent on their ability to detect cancers at their earliest stages. Proteomic analyses of early-stage cancers have provided new insights into the changes that occur in the early phases of tumorigenesis and represent a new resource of candidate biomarkers for early-stage disease. Studies that profile proteomic patterns in body fluids also present new opportunities for the development of novel, highly sensitive diagnostic tools for the early detection of cancer.
医生有效治疗和治愈癌症的能力直接取决于他们在癌症最早期阶段进行检测的能力。对早期癌症的蛋白质组学分析为肿瘤发生早期阶段所发生的变化提供了新的见解,并代表了早期疾病候选生物标志物的新资源。对体液中的蛋白质组模式进行分析的研究也为开发用于早期检测癌症的新型、高灵敏度诊断工具带来了新机遇。